Proposed NIH Budget Cuts Threaten HIV Breakthroughs Like Lenacapavir, Article Argues

Summary

The article argues that proposed Trump administration cuts to NIH funding—specifically a ~40% reduction to $27.9 billion for FY2026—would severely damage public health infrastructure. It uses the development of lenacapavir, a groundbreaking HIV drug, as a case study to demonstrate how decades of publicly funded basic research at NIH were essential to the breakthrough. The piece contends that such biomedical advances depend on sustained federal investment in fundamental science, which private industry alone cannot replace.